Philip Morris International (PMI) saw its shares rise 5.6% following FDA guidance favoring its IQOS product, yet the company also cut its annual profit forecast, ending a six-session winning streak. While PMI reported a year-over-year revenue growth of 9.1%, reflecting robust demand for its smoke-free products, it is navigating challenges with a new CFO, Massimo Andolina, stepping in to manage financial strategies. The company maintains an optimistic outlook with projected adjusted earnings per share for 2026 between $8.36 and $8.51, amidst a commitment to its transition to smoke-free tobacco alternatives.
“Philip Morris International · shares jumped · 5.6% · after the U.S. Food and Drug Administration issued new guidance”
“Philip Morris International shares · snapped · six session winning streak”
“Broyhill · trims · Philip Morris International”
“Philip Morris · cuts · annual profit forecast · bearish”
“Philip Morris International · appointed · Massimo Andolina · chief financial officer”
“Philip Morris International · has positioned itself as · a company whose alternative tobacco products are the growth story”
“Philip Morris International · showed net revenue rising · year over year · 9.1%”
“Philip Morris International · updated full-year 2026 adjusted EPS guidance to · a range of $8.36 to $8.51”
“Philip Morris International · pays an annual dividend of · $5.76”
“Philip Morris International · has a payout ratio of · 81%”
“Massimo Andolina · has been appointed · Group Chief Financial Officer · August 1, 2026”
“Philip Morris International · is · a tobacco company · true”